Shares of Coherus Biosciences (NASDAQ: CHRS) are soaring higher today after the biopharma company disclosed through an SEC filing that it's one step closer to receiving marketing approval in the European Union for its first clinical product.At the Committee for Medicinal Products for Human Use (CHMP) meeting in June, regulators raised several questions about the company's lead drug candidate, CHS-1701.